Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 1 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical StudyNot yet recruitingNCT07894367Phase 2
• Ceritinib Treatment for Recurrent MeningiomasNot yet recruitingNCT07893197Phase 2
• Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingNCT07892274Phase 3
• Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)Not yet recruitingNCT07888569Phase 1
• SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal CancerRecruitingNCT07888309Phase 2
• MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingNCT07885709Phase 2
• A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNot yet recruitingNCT07885293Phase 3
• Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyNot yet recruitingNCT07878871Phase 2
• Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular CarcinomaNot yet recruitingNCT07878689Phase 1/2
• Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)Not yet recruitingNCT07875972Phase 1
• Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingNCT07874425Phase 2
• MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLCNot yet recruitingNCT07873086Not applicable
• Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to RelapseRecruitingNCT07871864Phase 3
• A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)Not yet recruitingNCT07871721Phase 3
• Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingNCT07871110Phase 2
• A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on VelzatinibNot yet recruitingNCT07867171Phase 1
• A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental VitiligoNot yet recruitingNCT07865312Phase 3
• An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingNCT07863167Phase 2
• A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingNCT07863141Phase 2
• A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic TherapyNot yet recruitingNCT07862998Phase 2
• A Study to Investigate the Effects of Impaired Hepatic Function on VelzatinibNot yet recruitingNCT07859735Phase 1
• A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSRecruitingNCT07855276Phase 1
• Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal FunctionRecruitingNCT07853131Phase 1
• A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsRecruitingNCT07849231Phase 1
• Abrocitinib Dose Tapering in Patients With Atopic DermatitisNot yet recruitingNCT07848074Phase 4
• Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingNCT07847710Phase 2
• Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingNCT07847359Phase 2
• Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruitingNCT07846267Phase 2
• JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1DNot yet recruitingNCT07845955Phase 2
• Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingNCT07845786Phase 2
• Lenvatinib in Patients With Advanced Parathyroid CarcinomaNot yet recruitingNCT07843901Phase 2
• A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersRecruitingNCT07843693Phase 1
• A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)Not yet recruitingNCT07843641Phase 2
• A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor MonotherapyNot yet recruitingNCT07843550Phase 1/2
• Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingNCT07840976Phase 2
• Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingNCT07840456Phase 2
• Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingNCT07839247Phase 2
• A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdNot yet recruitingNCT07836257Phase 2
• Lenvatinib Plus Chemotherapy for pNET Liver MetastasesRecruitingNCT07835893Phase 2
• A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCTNot yet recruitingNCT07832747Phase 2
• Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingNCT07831395Phase 2
• Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingNCT07830355Phase 2
• Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver CancerNot yet recruitingNCT07829926Phase 2
• Safety and Efficacy of Soquelitinib in Adults With Hidradenitis SuppurativaRecruitingNCT07828860Phase 1
• PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCCNot yet recruitingNCT07827807Phase 2
• A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial CancerNot yet recruitingNCT07827612Phase 2
• Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of AgeNot yet recruitingNCT07823595Phase 3
• A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection (RET)-Altered Cancers in IndiaNot yet recruitingNCT07822880Phase 4
• A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric CancerNot yet recruitingNCT07819019Phase 2
• MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasNot yet recruitingNCT07816770Phase 2
• A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07816380Phase 3
• Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 WeeksRecruitingNCT07816328Phase 3
• A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCRecruitingNCT07815223Phase 2
• Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingNCT07814859Phase 2
• Ivarmacitinib Versus Glucocorticoids in Mild-to-Moderate Systemic Lupus ErythematosusNot yet recruitingNCT07814664Phase 2/3
• Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialNot yet recruitingNCT07812246Phase 2
• A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)RecruitingNCT07811869Phase 3
• Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic ImpairmentRecruitingNCT07809802Phase 1
• Asciminib Frontline Risk AdaptedNot yet recruitingNCT07804901Phase 2
• Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaRecruitingNCT07804186Phase 3
• Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLCNot yet recruitingNCT07802834Phase 2
• GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDACNot yet recruitingNCT07802184Phase 1/2
• Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)Not yet recruitingNCT07801248Phase 1
• A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingNCT07799220Phase 2
• Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBCRecruitingNCT07797218Phase 3
• Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNINot yet recruitingNCT07796620Phase 1/2
• Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingNCT07796373Phase 2
• Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingNCT07796113Phase 2
• Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersNot yet recruitingNCT07791199Phase 3
• A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
• A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without FoodRecruitingNCT07789028Phase 1
• Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)Not yet recruitingNCT07785388Phase 1/2
• Study of NXP900 With Lorlatinib in ALK+ Lung CancerRecruitingNCT07784959Phase 1
• A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingNCT07784101Phase 3
• Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumRecruitingNCT07783412Phase 2
• Topical JAK-Inhibition of Early-Stage CTCLNot yet recruitingNCT07781449Phase 2
• Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2
• The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07780578Phase 2
• Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory FailureNot yet recruitingNCT07779642Phase 2
• A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple SclerosisRecruitingNCT07776743Phase 2
• TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07776717Phase 2
• Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT07776080Phase 2
• Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid TumorsNot yet recruitingNCT07773454Phase 1
• Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingNCT07773363Phase 2
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingNCT07772492Phase 3
• A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial SpondyloarthritisNot yet recruitingNCT07770646Phase 4
• A 52-week Study of Remibrutinib in IgE-mediated Food AllergyRecruitingNCT07768371Phase 3
• Tucatinib Continuation StudyNot yet recruitingNCT07768358Phase 4
• Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingNCT07766772Phase 2
• Evaluation of PAN-90806 Eye Drops in Healthy SubjectsNot yet recruitingNCT07764965Phase 1
• Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingNCT07754890Phase 1/2
• STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter MethylationNot yet recruitingNCT07754734Phase 2
• Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingNCT07753642Phase 2
• Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)RecruitingNCT07753603Phase 3
• A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNot yet recruitingNCT07752108Phase 3
• Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCNot yet recruitingNCT07750704Phase 2
• Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
• A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2
• SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Phase 2
• Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingNCT07745296Phase 3

← Tyrosine Kinase Inhibitors overview